Published in Clin Cancer Res on December 01, 1999
Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer (2008) 3.04
Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. Cancer Res (2006) 1.35
Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin Exp Metastasis (2003) 1.13
Overexpression of bone sialoprotein leads to an uncoupling of bone formation and bone resorption in mice. J Bone Miner Res (2008) 1.04
Transfection of MDA-MB-231 human breast carcinoma cells with bone sialoprotein (BSP) stimulates migration and invasion in vitro and growth of primary and secondary tumors in nude mice. Clin Exp Metastasis (2004) 1.00
Targeted overexpression of BSP in osteoclasts promotes bone metastasis of breast cancer cells. J Cell Physiol (2009) 0.99
Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation. Br J Cancer (2006) 0.96
Expression of bone sialoprotein and osteopontin in breast cancer bone metastases. Clin Exp Metastasis (2000) 0.93
A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events. Breast Cancer Res Treat (2014) 0.93
Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers. Crit Rev Oncol Hematol (2013) 0.88
Bone resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis. Clin Exp Metastasis (2008) 0.87
Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma. Br J Cancer (2001) 0.86
Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Res Treat (2012) 0.84
High bone sialoprotein (BSP) expression correlates with increased tumor grade and predicts a poorer prognosis of high-grade glioma patients. PLoS One (2012) 0.83
Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases. Springerplus (2014) 0.82
Bone remodeling markers and bone metastases: From cancer research to clinical implications. Bonekey Rep (2015) 0.80
Sustained conditional knockdown reveals intracellular bone sialoprotein as essential for breast cancer skeletal metastasis. Oncotarget (2014) 0.80
Silencing of skeletal metastasis-associated genes impairs migration of breast cancer cells and reduces osteolytic bone lesions. Clin Exp Metastasis (2012) 0.79
The role of the bone microenvironment in skeletal metastasis. J Bone Oncol (2012) 0.79
Bisphosphonates in the adjuvant treatment of cancer: experimental evidence and first clinical results. International Bone and Cancer Study Group (IBCG). Br J Cancer (2000) 0.78
Effect of zoledronic acid and an antibody against bone sialoprotein II on MDA-MB-231(GFP) breast cancer cells in vitro and on osteolytic lesions induced in vivo by this cell line in nude rats. Clin Exp Metastasis (2007) 0.78
Applications of transgenics in studies of bone sialoprotein. J Cell Physiol (2009) 0.77
BSP gene silencing inhibits migration, invasion, and bone metastasis of MDA-MB-231BO human breast cancer cells. PLoS One (2013) 0.77
Bone metastasis risk factors in breast cancer. Ecancermedicalscience (2017) 0.75
Matricellular proteins as regulators of cancer metastasis to bone. Matrix Biol (2016) 0.75
Alteration of bone sialoprotein expression in osseous metastasized renal cell carcinomas and the tumor surrounding tissue. Clin Exp Metastasis (2011) 0.75
[Clinical relevance of biomarkers in cancer related bone disease]. Wien Med Wochenschr (2007) 0.75
Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med (1998) 6.09
Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med (1997) 3.91
Energetic crosstalk between organelles: architectural integration of energy production and utilization. Circ Res (2001) 2.77
Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J (2001) 2.52
Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst (1996) 2.51
Large and sustained induction of chemokines during impaired wound healing in the genetically diabetic mouse: prolonged persistence of neutrophils and macrophages during the late phase of repair. J Invest Dermatol (2000) 2.42
Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer (1995) 2.38
Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat (2000) 2.33
Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci U S A (1987) 2.29
The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int (2000) 2.14
Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med (2001) 1.88
The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Osteoporos Int (2009) 1.85
Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy (1999) 1.83
Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis. Osteoporos Int (2012) 1.80
Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim Biophys Acta (2000) 1.77
Acupuncture compared to placebo-acupuncture for postoperative nausea and vomiting prophylaxis: a randomised placebo-controlled patient and observer blind trial. Anaesthesia (2004) 1.71
Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol (2009) 1.69
Advanced abdominal pregnancy. Obstet Gynecol Surv (1991) 1.67
Circaannual rhythms and interactions of vitamin D metabolites, parathyroid hormone, and biochemical markers of skeletal homeostasis: a prospective study. J Bone Miner Res (2000) 1.66
Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood (1994) 1.64
Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol (2008) 1.59
Counterregulation of interleukin-18 mRNA and protein expression during cutaneous wound repair in mice. J Invest Dermatol (1999) 1.58
Leptin enhances wound re-epithelialization and constitutes a direct function of leptin in skin repair. J Clin Invest (2000) 1.45
Comparison of total and bone-specific alkaline phosphatase in patients with nonskeletal disorder or metabolic bone diseases. Clin Chem (1996) 1.45
Effects of transforming growth factor-beta on osteoblastic osteosarcoma cells. Endocrinology (1987) 1.42
Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J Clin Endocrinol Metab (2001) 1.42
Randomized trial on the effect of radiotherapy in addition to 6 cycles CMF in node-positive breast-cancer patients. The German Breast-Cancer Study Group. Int J Cancer (2000) 1.42
[The prevention of osteoporosis]. Dtsch Med Wochenschr (2001) 1.39
Prognostic effect of timing of surgery during menstrual cycle in premenopausal breast-cancer patients. German Breast Cancer Study Group. Int J Cancer (1994) 1.39
Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. German Breast Cancer Study Group. J Clin Oncol (1994) 1.38
Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer (2004) 1.38
Treatment of the twin-twin transfusion syndrome: initial experience using laser-induced interstitial thermotherapy. Fetal Diagn Ther (1997) 1.38
Ultrasound control for presumed difficult epidural puncture. Acta Anaesthesiol Scand (2001) 1.36
Ceramide-binding and activation defines protein kinase c-Raf as a ceramide-activated protein kinase. Proc Natl Acad Sci U S A (1996) 1.34
Two distinct signaling pathways trigger the expression of inducible nitric oxide synthase in rat renal mesangial cells. Proc Natl Acad Sci U S A (1994) 1.33
The pregnancy hormone relaxin is a player in human heart failure. FASEB J (2001) 1.32
Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. J Clin Oncol (1992) 1.32
Hypoxia induces macrophage inflammatory protein-2 (MIP-2) gene expression in murine macrophages via NF-kappaB: the prominent role of p42/ p44 and PI3 kinase pathways. FASEB J (2004) 1.31
Breastfeeding and breast cancer risk by age 50 among women in Germany. Cancer Causes Control (2000) 1.31
The function of nitric oxide in wound repair: inhibition of inducible nitric oxide-synthase severely impairs wound reepithelialization. J Invest Dermatol (1999) 1.29
Evaluation of urinary hydroxypyridinium crosslink measurements as resorption markers in metabolic bone diseases. Eur J Clin Invest (1991) 1.28
Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer (1994) 1.25
Atrial natriuretic peptide inhibits renin release from juxtaglomerular cells by a cGMP-mediated process. Proc Natl Acad Sci U S A (1986) 1.25
Serum parathyroid hormone is associated with increased mortality independent of 25-hydroxy vitamin d status, bone mass, and renal function in the frail and very old: a cohort study. J Clin Endocrinol Metab (2004) 1.25
Effect of Leboyer childbirth on cardiac output, cerebral and gastrointestinal blood flow velocities in full-term neonates. Am J Perinatol (1995) 1.24
[Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy]. Geburtshilfe Frauenheilkd (1994) 1.22
Maternal mortality in the main referral hospital in The Gambia, west Africa. Trop Med Int Health (1996) 1.21
Transforming growth factor beta inhibits formation of osteoclast-like cells in long-term human marrow cultures. Proc Natl Acad Sci U S A (1988) 1.20
Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW). Osteoporos Int (2010) 1.19
Expression and release of IL-18 binding protein in response to IFN-gamma. J Immunol (2001) 1.19
Seasonal variation of biochemical indexes of bone turnover: results of a population-based study. J Clin Endocrinol Metab (1998) 1.17
Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. Br J Cancer (2002) 1.17
Nitric oxide triggers enhanced induction of vascular endothelial growth factor expression in cultured keratinocytes (HaCaT) and during cutaneous wound repair. FASEB J (1999) 1.16
Functional coupling of creatine kinases in muscles: species and tissue specificity. Mol Cell Biochem (1998) 1.15
Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells. Cytotherapy (2005) 1.15
Molecular mechanisms of inducible nitric oxide synthase gene expression by IL-1beta and cAMP in rat mesangial cells. J Immunol (1998) 1.14
Pertussis toxin abolishes angiotensin II-induced phosphoinositide hydrolysis and prostaglandin synthesis in rat renal mesangial cells. Biochem J (1986) 1.14
Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone (1996) 1.14
Ultrasound imaging facilitates localization of the epidural space during combined spinal and epidural anesthesia. Reg Anesth Pain Med (2001) 1.13
Role of phospholipase C and protein kinase C in vasoconstrictor-induced prostaglandin synthesis in cultured rat renal mesangial cells. Biochem J (1986) 1.13
Characteristics associated with long-term progression-free survival following high-dose chemotherapy in metastatic breast cancer and influence of chemotherapy dose. Ann Oncol (2002) 1.13
Activation of phospholipase C and prostaglandin synthesis by [arginine]vasopressin in cultures. Biochem J (1984) 1.12
Targeted intervention reduces refracture rates in patients with incident non-vertebral osteoporotic fractures: a 4-year prospective controlled study. Osteoporos Int (2010) 1.12
Influence of fall related factors and bone strength on fracture risk in the frail elderly. Osteoporos Int (2007) 1.11
Molecular mechanisms of dexamethasone inhibition of nitric oxide synthase expression in interleukin 1 beta-stimulated mesangial cells: evidence for the involvement of transcriptional and posttranscriptional regulation. Proc Natl Acad Sci U S A (1996) 1.11
Expressional regulation of angiopoietin-1 and -2 and the tie-1 and -2 receptor tyrosine kinases during cutaneous wound healing: a comparative study of normal and impaired repair. Lab Invest (2001) 1.11
Stimulation by extracellular ATP and UTP of the mitogen-activated protein kinase cascade and proliferation of rat renal mesangial cells. Br J Pharmacol (1994) 1.10
Upregulation of group IB secreted phospholipase A(2) and its M-type receptor in rat ANTI-THY-1 glomerulonephritis. Kidney Int (2006) 1.10
Activation of protein kinase C subtypes alpha, gamma, delta, epsilon, zeta, and eta by tumor-promoting and nontumor-promoting agents. Biochem Pharmacol (1997) 1.09
Platelet-derived growth factor and angiotensin II stimulate the mitogen-activated protein kinase cascade in renal mesangial cells: comparison of hypertrophic and hyperplastic agonists. Biochem J (1995) 1.09
Looking beyond low bone mineral density: multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy. J Endocrinol Invest (2007) 1.09
Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf (1999) 1.09
The lumbar epidural space in pregnancy: visualization by ultrasonography. Br J Anaesth (2001) 1.09
Decorin deficiency in diabetic mice: aggravation of nephropathy due to overexpression of profibrotic factors, enhanced apoptosis and mononuclear cell infiltration. J Physiol Pharmacol (2009) 1.08
Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW). Osteoporos Int (2012) 1.07
Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res (1994) 1.07
Tumour promotor 12-O-tetradecanoylphorbol 13-acetate inhibits angiotensin II-induced inositol phosphate production and cytosolic Ca2+ rise in rat renal mesangial cells. FEBS Lett (1986) 1.07
Inducible NO synthase: role in cellular signalling. J Exp Biol (1999) 1.06
Changes in bone turnover induced by aerobic and anaerobic exercise in young males. J Bone Miner Res (1998) 1.06
Anti-inflammatory effects of sevoflurane and mild hypothermia in endotoxemic rats. Acta Anaesthesiol Scand (2007) 1.06
Interferon-gamma mediates gene expression of IL-18 binding protein in nonleukocytic cells. Biochem Biophys Res Commun (2000) 1.06
Selective inhibition of cyclooxygenase 2. Biochem Pharmacol (1994) 1.06
Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study. BMJ (1996) 1.05
Ceramide binds to the CaLB domain of cytosolic phospholipase A2 and facilitates its membrane docking and arachidonic acid release. FASEB J (2000) 1.05
Role of isolated locoregional recurrence of breast cancer: results of four prospective studies. J Clin Oncol (2000) 1.05
Modifying effect of reproductive risk factors on the age at onset of breast cancer for German BRCA1 mutation carriers. J Cancer Res Clin Oncol (1997) 1.04
Role of protein kinase C in inhibition of renin release caused by vasoconstrictors. Am J Physiol (1986) 1.04
Telomerase activity correlates with tumor aggressiveness and reflects therapy effect in breast cancer. Int J Cancer (1998) 1.04
Effects of a multi-component exercise program and calcium-vitamin-D3-fortified milk on bone mineral density in older men: a randomised controlled trial. Osteoporos Int (2008) 1.03